Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2003

View Archived Issues

Company Profile: Adventrx Pharmaceuticals

Melatonin as a novel therapy for Alzheimer's disease

Beta-L-2'-Fd4C shows antiviral activity and favorable pharmacokinetics in HBV

Sulphamoylated estrogen derivatives show potential in treating drug-resistant breast cancer

Yamanouchi and GlaxoSmithKline to copromote Vesicare in U.S.

Enrollment opens in phase II trial of Tarceva in malignant glioma

Phase II trial preparations advance for Norwood Immunology technology

Incara selects AEOL-10150 as candidate for ALS

FDA approves Trileptal for children

Paratek claims non-antibacterial tetracyclines for cancer, stroke and lung injury

Novel antibacterial tetracyclines in Paratek development pipeline

Receptor tyrosine kinase inhibitors and their use reported by Theravance

Novel 5-HT2C receptor ligands and their use as antiobesity agents

Novel series of Syk kinase inhibitors covered by Boehringer Ingelheim patent

Phase II DCF-987 trial completes enrollment

Ceregene acquires rights to ALS gene therapy from Salk Institute

ViroPharma acquires maribavir rights from GlaxoSmithKline

FDA Advisory Committee schedules review of Metvix for basal cell carcinoma

SGN-35 selectively targets CD30-positive malignancies in models of Hodgkin's disease

Caprion and AstraZeneca collaborate on pain biomarker research

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...